【摘要】 多系统萎缩(MSA)是一种快速进展的神经退行性疾病，主要表现为帕金森病样症状群、小脑性共济失调和自主神经功能障碍等多种临床症状。目前临床上用于诊断MSA的生物标志物缺乏特异性，早期诊断困难，容易误诊。MRI和脑脊液(CSF)检查可辅助诊断MSA,但成本较高且特异性低；MSA最新的早期检测技术α-突触核蛋白正电子发射计算机断层扫描(PET)成像应用于临床还需要一定时间；血液和尿液α-突触核蛋白检测技术有可能用于临床诊断；神经丝轻链(NfL)和胶质纤维酸性蛋白(GFAP)也可作为MSA诊断的生物标志物，但仍需进一步研究。研发用于MSA诊断的精准分子生物学标志物至关重要，它可以彻底改变MSA的诊断和治疗，有助于疾病的早期干预及改善预后。更多还原

【Abstract】 Multiple system atrophy(MSA) is a rapidly progressive neurodegenerative disease characterized by a variety of clinical symptoms such as Parkinson’s disease-like symptom clusters, cerebellar ataxia and autonomic dysfunction. At present, the biomarkers used in clinical diagnosis of MSA lack specificity, which makes early diagnosis difficult and easy to misdiagnose. MRI and cerebro spinal fluid(CSF) examination can assist in the diagnosis of MSA, but they are costly and have low specificity. It will take some time for the latest early detection technology of MSA, α-synuclein positron emission computed tomography(PET) imaging, to be applied in clinical practice. Blood and urine α-synuclein testing has the potential to be used in clinical diagnosis. Neurofilament light chain(NfL) and glial fibrillary acidic protein(GFAP) can also be used as biomarkers for the diagnosis of MSA, but further research is needed. The development of precise molecular biomarkers for the diagnosis of MSA is crucial, as it can revolutionize the diagnosis and treatment of MSA, and will facilitate early intervention and improve prognosis of the disease.更多还原